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Summary and Key Points 
1. Medical oncologists are internists specializing in the care of the 
adult cancer patient. They frequently function as a primary care 
physician for patients with cancer. Pediatric hematology/oncology 
is a separate subspecialty, covered in a separate chapter, 
Pediatric Oncology Principles. 
2. Medical oncologists often direct the evaluation of patients with 
newly diagnosed cancers, maintain ongoing follow-up of cancer 
patients after initial treatment has ended, and often supervise 
hospice care for cancer patients at the end of life. 
3. Medical oncologists prescribe chemotherapy to treat cancer. 
4. Chemotherapy refers to drug therapy and usually is used to treat 
the whole body, although few drugs effectively penetrate the brain. 
5. “Chemotherapy” refers to over 100 different drugs that are used to 
treat cancers. Each drug has a unique mechanism of action and 
unique side effects. 
6. Only a small number of cancers are able to be cured when treated 
solely with chemotherapy. 
7. Chemotherapy can improve cure rates of cancers when given in 
conjunction with surgery and/or radiation. 
8. Chemotherapy can prolong survival in patients with incurable 
cancers and can also relieve symptoms caused by cancers. 
9. Patients receiving chemotherapy must be assessed frequently to 
prevent intolerable side effects and ensure the chemotherapy is 
working against the cancer that is being treated. 
Introduction 
Medical oncology is the branch of Internal Medicine that specializes in 
the treatment of cancer in adult patients. Most medical oncologists are 
also hematologists, who specialize in the treatment of hematologic 
malignancies (the leukemias, lymphomas and myelodysplastic 
syndromes) as well as benign blood disorders and blood treatments. 
Because the most common pediatric malignancy is leukemia, pediatric 
oncologists are always hematologist/oncologists. Since medical 
oncologists are internists or pediatricians, they manage the complex 
medical conditions which frequently occur in cancer patients. Medical 
oncologists also prescribe chemotherapy. 
Medical oncology developed after the introduction of modern drug 
treatment for cancer, which began after World War II. Informal training 
was available by the early 1960s, but medical oncology was only 






Modern drug treatment of cancer dates to World War II when Gilman and 
colleagues launched the first clinical trials of nitrogen mustard. Since 
then, over one hundred different drugs have been approved in the United 
States for the treatment of cancer. While the general public– and many 
physicians– commonly lump all these drugs under the name 
“chemotherapy”, there is tremendous variation in the mode of action and 
toxicity of these different compounds. Anti-cancer drugs can work by 
mobilizing the immune system (e.g., interleukin-2, ipilumumab), blocking 
hormones (e.g., tamoxifen), interrupting intracellular pathways (e.g., 
temsirolimus), or mutating DNA (e.g., nitrogen mustard) to list a few 
mechanisms of their actions. Similarly, side effects from antineoplastics 
can range from life-threatening bone marrow suppression to emotionally 
distressing alopecia. Despite the fact that these drugs may all be labeled 
“chemotherapy”, it should be appreciated that there are different 
indications, mechanisms, and toxicities for each agent. 
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This chapter will review the practice of medical oncology and some 
general principles followed in the use of chemotherapy. Concepts 
including goals of chemotherapy treatment, evaluation of the effects of 
chemotherapy, integration of chemotherapy with other cancer 
treatments, and use of combinations of chemotherapy drugs will be 
covered. Those interested in specific aspects of the drugs are referred to 
the section on chemotherapy of neoplastic diseases in Goodman and 
Gilman’s The Pharmacological Basis of Therapeutics. 
The Practice of Medical Oncology 
Medical Oncologists are internists with three years of residency in 
Internal Medicine before they start training in Oncology. As a result, they 
are prepared to manage all of the complex medical issues that arise 
during the course of treatment, whether caused by the treatment or by 
underlying conditions, with the same consultative support from other 
specialists that primary care physicians would require. 
Included among the many conditions managed by medical oncologists 
are febrile neutropenia, sepsis, anemia, thrombocytosis, 
thrombocytopenia, deep venous thrombosis, seizures, elevated blood 
sugar, peripheral neuropathy  dehydration tumor lysis syndrome, and 
metabolic derangements, all of which can be caused by chemotherapy, 
and some of which may be caused by  cancer. They must be prepared to 
manage severe pain. They often have to refer to another specialist for 
help with tumor bleeding or a pathologic fracture. 
In addition, Medical Oncologists must understand the randomized trial 
data justifying the use of each chemotherapy regimen, the risks and 
benefits of each drug and drug combination, and the interaction of each 
regimen with patient’s comorbid conditions, such as diabetes, renal 
failure or heart disease. Specialized oncologists prescribe and supervise 
bone marrow transplantation, a set of treatments which requires 
intensive care level skills. 
In the United States, medical oncologists are the physicians who admit 
most cancer patients to the hospital, except for patients who require a 
surgical intervention. A good Medical Oncologist views his/her practice 
as providing a medical home for the oncology patient during and shortly 
after the course of treatment. They are the physicians most likely to 
provide supervision for hospice care for their patients 
Goals of Chemotherapy Treatment 
When faced with a problem, it is natural to want to find a solution. 
Meeting a patient with a malignancy, it is understandable that a 
physician’s first hope is to find a cure for the patient’s cancer. 
Unfortunately, many human cancers are simply not curable at present. 
Before initiating any anti-cancer treatment, it is important to ask what the 
goal of treatment is. If cure is possible, then that should be the goal of 
treatment and both patient and physician may be willing to accept side 
effects of treatment in exchange for cure. If cure is not possible, then 
goals may be more modest, such as prolongation of life or relief of 
symptoms. In such circumstances, choices of treatment may be greatly 
affected by considerations of complications of treatment. This section will 
consider the use of chemotherapy in anti-cancer treatment based on 
treatment goals. 
Treatment for Cure 
Table 1 lists the cancers that are curable, even at an advanced stage, 
with chemotherapy alone. For the most part, the curative regimens for 
these diseases involve multiple chemotherapy agents given at well-
established doses and schedules. Many of these regimens have evolved 
over decades of clinical trials (e.g., treatment of childhood acute 
lymphoblastic leukemia) while others have not changed in a quarter-
century (e.g., treatment of germ cell tumors). Over the past fifty years, a 
fundamental principle of curative chemotherapy regimens has been that 
a complete response to treatment is necessary to achieve a cure. A 
complete response is defined as the eradication of all known tumor as 
assessed by physical exam, imaging studies such as CT or other scans, 
and, when indicated, biopsy of involved areas such as bone marrow. 
Unfortunately, while cure is impossible in the absence of a complete 
response, relapse of undetected microscopic cancer can and does 
happen in patients who appear to have achieved a complete response. 
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All of the treatments for the diseases listed in Table 1 are given for a 
defined period of time, after which treatment is stopped and patients are 
then either cured or fated to relapse at some point in the future. New 
drugs have challenged the idea that intensive, limited treatment with 
complete eradication of all tumor cells is the only way to control cancer. 
These drugs also force us to revise our understanding of what 
constitutes “cure”. Imatinib is highly active against chronic myeloid 
leukemia (CML) with complete response rates of over 90% and 5-year 
disease free rates of 85-90%. However, it appears that it is necessary for 
patients to stay on imatinib for a long time, possibly life-long, as relapse 
of CML has occurred in patients who stop the drug even after years of 
use. In a sense, one can think of current treatment of the cancers listed 
in Table 1 as analogous to treatment of many bacterial infections where 
patients are cured after short courses of antibiotics. By contrast, 
treatment of CML with imatinib can be likened to treatment of other 
chronic diseases (hypertension, diabetes, HIV) where continuous 
treatment controls disease and permits long term survival. 
While the list of diseases cured solely by chemotherapy is short, there 
are many cancers in which the use of chemotherapy in combination with 
surgery and/or radiation will markedly increase cure rates. In most of 
these settings chemotherapy is considered an “adjuvant” (or aide) to the 
“primary” treatment of surgery or radiation. “Neoadjuvant” chemotherapy 
refers to giving chemotherapy before the patient undergoes surgery or 
radiation, while “adjuvant” chemotherapy is given after primary surgery or 
radiation. In either setting, the use of chemotherapy in addition to surgery 
or radiation is believed to improve survival by eradicating microscopic 
metastatic disease not cured or removed by the local treatment. Table 2 
lists diseases for which adjuvant or neoadjuvant chemotherapy is 
commonly employed. In each case, the diseases are early-stage, that is, 




The use of chemotherapy in the neoadjuvant or adjuvant setting results 
in a different distribution of patient outcomes than occurs with the use of 
curative chemotherapy for diseases listed in Table 1. For example, 
patients with Stage IV diffuse large cell non-Hodgkin lymphoma will all 
die without treatment but have a 40-50% probability of cure with current 
standard chemotherapy. By contrast, a 60 year old woman with a 2.5 cm 
estrogen-receptor positive, lymph node negative breast cancer has about 
a 60% chance of being relapse-free ten years after mastectomy or 
lumpectomy and breast irradiation without any additional chemotherapy. 
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If that patient receives an anti-estrogen therapy like an aromatase 
inhibitor for five years after her surgery, her probability of relapse-free 
survival at ten years improves to 77%. If she takes chemotherapy in 
addition to her aromatase inhibitor after surgery, her probability of 
relapse-free survival at ten years is now 84%.
3
 In the case of patients 
with Stage IV non-Hodgkin lymphoma, chemotherapy is the only 
treatment modality that results in a meaningful chance of cure. However, 
surgery will cure the majority of women with early stage breast cancer 
and the use of chemotherapy in such patients, while improving overall 
survival, results in over-treatment of those who were cured by their 
surgery. A major goal of clinical research is to better define patients who 
will benefit from adjuvant or neoadjuvant chemotherapy to avoid 
exposing those patients who do not require chemotherapy to potential 
side effects of over-treatment. 
Neoadjuvant chemotherapy is most often employed in situations for 
which surgery may result in a significant functional or cosmetic defect 
(e.g., laryngeal or anal cancer or breast cancer). In these settings, 
eradication of the primary tumor by chemotherapy – given with radiation 
in some diseases – can eliminate the need for or lessen the extent of 
subsequent surgery. Neoadjuvant chemotherapy can also be given in 
settings in which it is better tolerated than post-operative chemotherapy 
(e.g., rectal cancer). 
Treatment for Palliation of Symptoms or Prolongation of Life 
In the large number of advanced cancers for which cure is not possible, 
the major goals of any treatment, including chemotherapy, are to relieve 
symptoms of the cancer and prolong life. There is now good evidence 
that current chemotherapy can result in significant prolongation of life in 
a number of common tumors, including metastatic lung, breast, and 
colorectal cancers. Quality of life studies are increasingly incorporated 
into clinical trials of chemotherapy in advanced malignancies, making it 
possible to identify drugs which can reduce symptoms of cancer even if 
they have no or minimal impact on the duration of survival. 
Given that a major goal of treatment of advanced cancers is the relief of 
symptoms; it becomes a Pyrrhic victory if metastatic tumors are shrunk at 
the expense of diminished quality of life from excessive chemotherapy 
toxicity. Careful monitoring of patients throughout treatment is essential. 
Many side effects of chemotherapy can be managed with simple, 
inexpensive treatments such as anti-emetics for nausea, mouth washes 
for stomatitis, or creams for rashes. Other toxicities will require 
reductions in chemotherapy doses or delays in treatment for symptoms 
to resolve. Note that this approach is in contrast to the treatment of 
curable malignancies where dose delays or reductions can compromise 
the chance of cure or long term survival. In addition to careful monitoring 
of patients, constant communication with patients throughout treatment is 
also vital. Some patients with advanced tumors may accept an increased 
risk of side effects from treatment if their major goal is prolongation of 
life; others may wish to spend as little time as possible in the clinic or 
hospital receiving treatment or prefer to forgo a chance at a somewhat 
longer life in favor of fewer complications of treatment. 
Evaluating Effects of Chemotherapy 
A fundamental principle of pharmacology is the therapeutic index. Easily 
defined, but somewhat difficult to calculate with precision, it is the benefit 
of a drug divided by the drug’s toxicity. Given the potential side effects of 
chemotherapy, it is easy to appreciate that the therapeutic index of 
chemotherapy can be small. Because of this, it is vital that patients 
undergoing chemotherapy treatment be continually re-assessed for the 
benefits and side effects of treatment. 
The most common assessment of benefit from chemotherapy is 
measurement of tumor response to treatment. This can be done via 
physical exam of palpable tumors, measurement of tumors found on 
radiographic studies, measurement of serum tumor markers, or repeated 
biopsies of areas of known tumor. A “partial response” to treatment is 
usually defined as a reduction by 50% or more of all known measurable 
tumors with no evidence of new tumor growth. As mentioned previously, 
a “complete response” is the eradication of all known tumor. “Progressive 
disease” has been defined as the appearance of new tumors or growth 
by 25% of existing tumors and “stable disease” is a cancer that has 
neither demonstrated a partial response nor progressed. The importance 
of these designations lies in the clinician’s use of them. It makes no 
sense, for example, to continue ineffective chemotherapy in a patient 
who has progressive disease on treatment. By contrast, it may be 
worthwhile to continue treatment in a patient who has developed a partial 
response or stable disease if their quality of life is acceptable on 
treatment. Finally, as previously noted, assessment of complete 
response is important in treating potentially curable tumors. 
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Assessment of side effects of treatment is as important as assessment of 
tumor response. Formal definitions and grading of side effects have been 
published
4
 and are routinely utilized in assessing treatments in clinical 
trials. Patients should be seen frequently while receiving chemotherapy 
and steps should be taken to prevent or alleviate side effects as soon as 
possible. Particularly in the patient with an incurable malignancy, it is 
imperative that the goals of treatment be continually evaluated in light of 
side effects of treatment. 
Integration of Chemotherapy with Other Anti-Cancer Treatments 
A common theme of this book is that many patients with cancer will 
require more than one kind of treatment. A patient with early stage breast 
cancer may undergo a lumpectomy, then receive post-operative 
(adjuvant) chemotherapy, receive radiation to the residual breast after 
chemotherapy is complete, and then conclude treatment by taking 
tamoxifen or an aromatase inhibitor for five to ten years. A patient with 
rectal cancer could start treatment with chemotherapy given concurrently 
with radiation, followed by surgery to remove residual tumor, and 
conclude treatment with additional chemotherapy. Another patient with 
limited stage small cell lung cancer will likely be treated with thoracic 
radiation given concurrently with chemotherapy, followed by additional 
chemotherapy, and then receive prophylactic cranial irradiation (PCI). 
Each of these cases demonstrate the variety of options facing patients 
and physicians treating cancer and highlights the need for good 
communication between medical, surgical, and radiation oncologists to 
coordinate care successfully. 
Concurrent chemotherapy and radiation have been shown to be superior 
to sequential treatments in a number of cancers. Theoretically, 
chemotherapy could treat microscopic metastatic disease that exists 
outside the radiation treatment field and so improve cure rates by 
preventing relapse of disease not treated by radiation. Additionally, a 
number of chemotherapy drugs can increase the radiation sensitivity of 
tumor cells. This property of radiation sensitization should lead to fewer 
relapses of tumors within the radiation field, compared to similar tumors 
treated with radiation alone. In fact, most successful trials of concurrent 
radiation and chemotherapy treatment have demonstrated a reduction in 
both local and distant cancer relapses with concurrent treatment as 
compared with sequential treatment or radiation treatment alone. 
However, concurrent treatment also comes with a higher cost of 
increased toxicity. In addition to the unique side effects that may be 
associated with any chemotherapy drug, chemotherapy given 
concurrently with radiation can increase the risk and severity of both 
acute and late side effects associated with radiation. 
Use of Combinations of Chemotherapy Drugs 
While individual chemotherapy drugs can have significant activity against 
tumors as assessed by tumor response rate, most regimens that are 
used to cure cancers (Tables 1 and 2) include multiple chemotherapeutic 
agents. Using drugs that are active against a malignancy but that have 
different side effect profiles should permit the use of maximal doses of 
more than one agent. If one is forced to lower the dose of an individual 
drug below a level that would be effective against a cancer in order to 
include that drug in a combination, then it is unlikely that the drug will add 
anything except side effects to the combination. Chemotherapy 
combinations should utilize drugs with different mechanisms of action. 
Because cancers are frequently composed of heterogeneous clones of 
cells that may express different sensitivities (or resistance) to different 
drugs, a combination of drugs which work by a variety of mechanisms 
may prevent the emergence of a clone of tumor cells that is resistant to a 
single agent. 
Combinations of chemotherapy drugs are also often used in the 
treatment of cancers that are incurable. A chemotherapy combination 
often results in higher tumor response rates than can be achieved if the 
drugs in the combination are used individually. While tumor response 
rates do not necessarily correlate with improvement in life span, tumor 
shrinkage may improve quality of life by relieving symptoms caused by 
the tumor. However, some chemotherapy combinations have produced 
longer survival of patients with advanced cancers compared with using 
single drugs sequentially. Combinations of chemotherapy drugs, 
however, are more likely to cause side effects than single drugs. As 
mentioned previously, it is critical that physicians communicate the goals 
and risks of treatments clearly with patients to help make a decision 
about the appropriateness of combination chemotherapy in the setting of 
an incurable malignancy. 
Evaluation of Patients After Anticancer Treatment Concludes 
After cancer treatment concludes, patients may benefit from monitoring 
for late side effects of treatment. There are a number of long term effects 
of treatment that can become very bothersome or even life threatening.  
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For example, peripheral neuropathy after treatment with oxaliplatin may 
persist for years. Similarly, myelodysplasia or acute myeloid leukemia 
can arise years after exposure to mustard compounds or topoisomerase 
inhibitors. While there are no guidelines that call for close monitoring of 
patients for the emergence of leukemia after chemotherapy treatment, 
physicians need to be aware of the potential for late complications to 
arise. 
In addition to monitoring patients for late side effects of treatment, most 
patients will continue to see their oncologist after treatment to be 
checked for possible recurrence of cancer. Many national groups have 
issued guidelines regarding appropriate testing and evaluation of 
patients after cancer treatment. In general, these guidelines are not 
based on evidence from clinical trials, but are the product of consensus 
from panels of “experts”. Nevertheless, it is probably helpful for patients 
to be informed at the end of treatment about the kind of monitoring they 
can expect to undergo. 
Conclusion 
Medical oncologists provide primary care for the cancer patient and also  
prescribe and supervise chemotherapy. Medical oncologists usually 
continue to see patients after their initial treatment is over, to assess for 
long term complications of treatment and evaluate the possibility of 
cancer recurrence. Medical oncologists frequently are the supervising 
physicians for patients with cancer who receive care in hospice. 
Chemotherapy treatment should be based on the goals of care of any 
particular patient. When cure of a cancer is the goal of treatment, the 
patient and physician may be willing to accept significant side effects of 
treatment. When cure is not possible, chemotherapy may be given to 
improve quality of life by relieving symptoms of cancer and also, 
possibly, to prolong life. In this setting, it is important that the oncologist 
communicate frequently with the patient to insure that side effects of 
treatment not become so burdensome that they outweigh the benefit of 
therapy. 
Chemotherapy can be given before or after definitive surgery to improve 
cure rates of many cancers. Chemotherapy can also be given before, 
after or during radiation therapy. In each of these settings, careful 
planning with surgeons and radiation oncologists is essential to produce 
a safe and effective treatment. 
Thought Questions 
1. In many parts of the world, chemotherapy for solid tumors is 
prescribed and supervised by oncologists who also supervise 
radiation therapy. In the United States, most gynecologic oncologists 
prescribe and supervise chemotherapy for their patients. What is the 
advantage of each approach? What are the disadvantages of each 
approach? Why are other organ system cancers  not treated by the 
surgical subspecialist who operates on them? Why do radiation 
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2. While chemotherapy can improve the cure rate of early stage breast 
cancers after surgery, current chemotherapy cannot cure Stage IV 
(metastatic) breast cancer. 
a) If chemotherapy has no effect on the curability of metastatic 
breast cancer, why is it possible for chemotherapy to improve 
















b) The same drugs used to treat patients with early stage breast 
cancer are also used to treat patients with metastatic disease. 
How might the stage of a patient's breast cancer affect the 





















Principles of Medical Oncology 
 
 
Cancer Concepts: A Guidebook for the Non-Oncologist   (15 March 2016) 
8 
3. Using two or more chemotherapy drugs concurrently frequently 
results in higher tumor shrinkage (response) rates than using the 
same drugs individually in sequence when treating metastatic 
cancers. However, in a number of metastatic cancers, there is no 
difference in overall survival regardless of whether patients are 
treated with concurrent or sequential combinations of chemotherapy. 
What might be the reasons to choose to give a patient with a 


























Adjuvant chemotherapy- Chemotherapy given after primary surgery or 
radiation 
Complete response- Eradication of all known tumor as assessed by 
physical exam, imaging studies such as CT or other scans, and, when 
indicated, biopsy of involved areas such as bone marrow 
Neoadjuvant chemotherapy- Chemotherapy given before surgery or 
radiation 
Partial response- Reduction by 50% or more of all known measurable 
tumors with no evidence of new tumor growth 
Prophylactic cranial irradiation (PCI)- Elective irradiation of the brain to 
attempt to prevent the later (expected) appearance of brain metastases 
Progressive disease- The appearance of new tumors or growth by 25% 
of existing tumors 
Pyrrhic victory- A victory with devastating losses 
Stable disease- A cancer that has neither demonstrates a partial 
response or progression 
Therapeutic index- Benefit of a drug divided by the drug’s toxicity 
References 
1. Band PR. The birth of the subspecialty of medical oncology and 
examples of its early scientific foundations. J Clin Oncol. 
2010;28(22):3653-58. 
PubMed Abstract 
2. Pearson HA. History of pediatric hematology oncology. Pediatr Res. 
2002;52(6):979-92. 
3. Adjuvant! Online: Decision making tools for healthcare professionals. 
Accessed 25 December 2010 
4. National Cancer Institute (NCI). Cancer Therapy Evaluation Program 
(CTEP). Common Terminology Criteria for Adverse Events (CTCAE). 
Accessed 12 November 2015. 
